Join our ambition to change the lives of those living with liver fibrosis

We are advancing a differentiated RNA therapeutics platform targeting a multibillion-dollar market with significant unmet medical need. Our technology, with a compelling pre-clinical data package and optimized for hepatocyte-specific delivery, offers first-in-class potential with a clear path to the clinic.

We are currently in active discussions with investors to fund our next stage of growth, allowing our experienced team to advance our lead candidate through to IND-enabling studies and expanding our pipeline.

If you share our vision for bringing breakthrough therapies to people living with serious liver disease we would welcome the opportunity to discuss our progress to date, the commercial opportunity and investment terms.

Reach out to us to schedule a meeting with our leadership team.